GleamWall
中文EN

NVCR NovoCure Ltd

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1645113 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.9%
TTM net income YoY31.5%
TTM EPS YoY34.2%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin-17.2%
Net margin-16.8%
FCF margin-3.4%
EBITDA margin-14.8%

Returns

ROE-35.2%
ROA-11.1%
ROIC (approx.)-77.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets57.7%
Debt / equity0.00x
Current ratio2.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.01x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$193.40M$183.58M$174.06M$174.35M$167.20M$158.81M$154.99M$161.27M
Cost of revenue$44.53M$41.11M$38.93M$42.16M$44.73M$41.47M$38.52M$33.47M
Gross profit$148.87M$142.48M$135.13M$132.19M$122.47M$117.33M$116.47M$127.80M
R&D expense$58.10M$51.45M$58.34M$60.91M$54.03M$55.83M$53.78M$51.21M
SG&A expense$43.65M$39.91M$85.85M$43.02M$45.92M$43.95M$44.77M$72.48M
Operating income-$6.17M-$10.56M-$67.42M-$40.39M-$36.02M-$39.52M-$37.87M-$63.30M
Pretax income-$7.88M-$12.45M-$69.26M-$40.95M-$30.02M-$34.98M-$30.30M-$55.21M
Income tax$2.56M$3.21M$1.88M-$16.45M$7.25M$5.16M$4.02M$10.72M
Net income-$10.44M-$15.66M-$71.14M-$24.50M-$37.27M-$40.14M-$34.32M-$65.92M
EBITDA-$1.75M-$6.25M-$63.30M-$36.17M-$32.36M-$36.08M-$34.54M-$60.20M
EPS (basic)-0.09-0.13-0.62—-0.33-0.36-0.31—
EPS (diluted)-0.09-0.13-0.62—-0.33-0.36-0.31—
Weighted avg. shares (diluted)116.79M116.01M114.15M—111.91M111.57M110.28M—
Balance sheet
Cash & equivalents$96.73M$103.62M$97.32M$93.55M$342.12M$152.13M$129.43M$166.09M
Receivables$108.26M$99.13M$93.27M$89.44M$85.23M$89.92M$84.51M$74.23M
Inventory$40.60M$42.22M$43.46M$41.11M$39.10M$40.21M$39.47M$35.09M
Current assets$673.52M$638.52M$631.66M$646.73M$1.20B$1.08B$1.09B$1.11B
PP&E, net$72.67M$75.37M$76.28M$77.61M$79.98M$80.33M$79.60M$77.66M
Total assets$828.71M$795.19M$787.93M$804.33M$1.36B$1.25B$1.25B$1.24B
Current liabilities$270.66M$220.71M$217.58M$223.23M$776.01M$749.63M$743.30M$756.39M
Short-term debt$25.00M——$0————
Long-term debt———$195.05M———$97.30M
Total debt———$195.05M———$97.30M
Total liabilities$478.10M$457.10M$457.21M$463.86M$1.02B$896.43M$886.85M$880.61M
Shareholders' equity$350.61M$338.09M$330.72M$340.47M$341.33M$349.44M$361.96M$360.18M
Net debt———$101.50M———-$68.79M
Shares outstanding116.91M116.44M115.82M112.49M111.98M111.80M111.48M108.52M
Cash flow statement
Operating cash flow$22.67M$8.13M-$13.52M-$18.00M$20.57M-$15.94M-$35.66M-$3.45M
Capital expenditure$6.92M$6.92M$5.15M$4.90M$5.66M$5.49M$10.61M$8.94M
Free cash flow$15.75M$1.22M-$18.67M-$22.90M$14.92M-$21.42M-$46.28M-$12.39M
Investing cash flow-$23.24M-$6.38M$7.75M$336.33M$71.44M$35.99M-$6.47M-$22.21M
Financing cash flow$3.64M$4.55M-$166,000-$559.49M$100.52M$2.39M$5.25M$2.69M
Depreciation & amortization$4.42M$4.31M$4.12M$4.22M$3.66M$3.44M$3.33M$3.10M
Stock-based compensation$17.48M$17.01M$63.01M$19.82M$29.32M$26.14M$29.55M$62.76M

Free plan shows the latest 8 periods; Pro shows all 49 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.